Applicant, as named in the Orange Book
Kai Pharms Inc
Amgen Inc · Nasdaq: AMGN
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Parsabiv on 27 Jun 2034. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Parsabiv NDA 208325 · 3 strengths etelcalcetide | 27 Jun 2034 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.